Cancer susceptibility and embryonic lethality in Mob1a/1b double-mutant mice
Open accessThe DOI matches its Crossref record; 6 of the 6 references it cites were found in a registry or an index.
Abstract
Mps one binder 1a (MOB1A) and MOB1B are key components of the Hippo signaling pathway and are mutated or inactivated in many human cancers. Here we show that intact Mob1a or Mob1b is essential for murine embryogenesis and that loss of the remaining WT Mob1 allele in Mob1a(Δ/Δ)1b(tr/+) or Mob1a(Δ/+)1b(tr/tr) mice results in tumor development. Because most of these cancers resembled trichilemmal carcinomas, we generated double-mutant mice bearing tamoxifen-inducible, keratinocyte-specific homozygous-null mutations of Mob1a and Mob1b (kDKO mice). kDKO mice showed hyperplastic keratinocyte progenitors and defective keratinocyte terminal differentiation and soon died of malnutrition. kDKO keratinocytes exhibited hyperproliferation, apoptotic resistance, impaired contact inhibition, enhanced progenitor self renewal, and increased centrosomes. Examination of Hippo pathway signaling in kDKO keratinocytes revealed that loss of Mob1a/b altered the activities of the downstream Hippo mediators LATS and YAP1. Similarly, YAP1 was activated in some human trichilemmal carcinomas, and some of these also exhibited MOB1A/1B inactivation. Our results clearly demonstrate that MOB1A and MOB1B have overlapping functions in skin homeostasis, and exert their roles as tumor suppressors by regulating downstream elements of the Hippo pathway.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Yap1 acts downstream of α-catenin to control epidermal proliferation
Schlegelmilch, K., Mohseni, M., Kirak, O., Pruszak, J., Rodriguez, J. R., Zhou, D., Kreger, B. T., Vasioukhin, V., Avruch, J., Brummelkamp, T. R., et al. (2011) · Cell · doi:10.1016/j.cell.2011.02.031 · Cited by 1,036
Gu, H., Zou, Y.-R., & Rajewsky, K. (1993) · Cell · doi:10.1016/0092-8674(93)90644-6 · Cited by 989 · cited 1×
“Correctly targeted Mob1a mutant clones were transiently transfected with pMC1-Cre (54) to delete the loxP -flanked Hyg r gene.”
The Salvador–Warts–Hippo pathway — an emerging tumour-suppressor network
Harvey, K., & Tapon, N. (2007) · Nature Reviews Cancer · doi:10.1038/nrc2070 · Cited by 628 · cited 3×
“The evolutionarily conserved Hippo signaling pathway was first identified as regulating the cell proliferation and apoptosis-con-trolling organ size in Drosophila (6, 7).”
Morin-Kensicki, E. M., Boone, B. N., Howell, M., Stonebraker, J. R., Teed, J., Alb, J. G., Magnuson, T. R., O'Neal, W., & Milgram, S. L. (2006) · Molecular and Cellular Biology · doi:10.1128/mcb.26.1.77-87.2006 · Cited by 429
Zhang, H., Pasolli, H. A., & Fuchs, E. (2011) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1019603108 · Cited by 419
Sudol, M., Bork, P., Einbond, A., Kastury, K., Druck, T., Negrini, M., Huebner, K., & Lehman, D. (1995) · Journal of Biological Chemistry · doi:10.1074/jbc.270.24.14733 · Cited by 342
Cited by
Hippo pathway in organ size control, tissue homeostasis, and cancer
Yu, F.-X., Zhao, B., & Guan, K.-L. (2015) · Cell · doi:10.1016/j.cell.2015.10.044 · Cited by 2,206
The Hippo pathway and human cancer
Harvey, K. F., Zhang, X., & Thomas, D. M. (2013) · Nature Reviews Cancer · doi:10.1038/nrc3458 · Cited by 1,842
The Biology of YAP/TAZ: Hippo Signaling and Beyond
Piccolo, S., Dupont, S., & Cordenonsi, M. (2014) · Physiological Reviews · doi:10.1152/physrev.00005.2014 · Cited by 1,802
Mechanisms of Hippo pathway regulation
Meng, Z., Moroishi, T., & Guan, K.-L. (2016) · Genes & Development · doi:10.1101/gad.274027.115 · Cited by 1,667
The Hippo pathway: regulators and regulations.
Yu, F.-X., & Guan, K.-L. (2013) · Genes & Development · doi:10.1101/gad.210773.112 · Cited by 1,231
The Hippo Signaling Pathway in Development and Disease
Zheng, Y., & Pan, D. (2019) · Developmental Cell · doi:10.1016/j.devcel.2019.06.003 · Cited by 867
“…of Mst1/2 in mouse has no discernable phenotype (Schlegelmilch et al., 2011), but deletion of the Lats1/2 cofactors Mob1a/b in the same tissue results in tumorigenesis, suggesting the operation of a potential Mst1/2-independent mechanism of Lats1/2 activation in this context (Nishio et al., 2012).”
BackgroundThe Hippo pathway effectors TAZ and YAP in development, homeostasis and disease
Varelas, X. (2014) · Development · doi:10.1242/dev.102376 · Cited by 665
“The knockout of both Mob1a and Mob1b, which are regulators of LATS1/2 activity, also results in developmental defects, with embryos arresting at around embryonic day (E) 6.5, prior to gastrulation (Nishio et al., 2012).”
BackgroundInfluentialRole of Hippo Pathway-YAP/TAZ Signaling in Angiogenesis
Boopathy, G. T. K., & Hong, W. (2019) · Frontiers in Cell and Developmental Biology · doi:10.3389/fcell.2019.00049 · Cited by 344
The Hippo pathway in intestinal regeneration and disease
Hong, A. W., Meng, Z., & Guan, K.-L. (2016) · Nature Reviews Gastroenterology & Hepatology · doi:10.1038/nrgastro.2016.59 · Cited by 326
Hippo Signaling in the Liver Regulates Organ Size, Cell Fate, and Carcinogenesis
Patel, S. H., Camargo, F. D., & Yimlamai, D. (2017) · Gastroenterology · doi:10.1053/j.gastro.2016.10.047 · Cited by 297
Characterization of Hippo Pathway Components by Gene Inactivation
Plouffe, S. W., Meng, Z., Lin, K. C., Lin, B., Hong, A. W., Chun, J. V., & Guan, K.-L. (2016) · Molecular Cell · doi:10.1016/j.molcel.2016.10.034 · Cited by 275
“This is consistent with reported animal studies that found that deletion of MOB1A and a homozygous null mutation in MOB1B resulted in increased YAP activity and hyper-proliferation (Nishio et al., 2012).”
Molecular Pathogenesis of Pancreatic Cancer
Grant, T. J., Hua, K., & Singh, A. (2016) · Progress in Molecular Biology and Translational Science · doi:10.1016/bs.pmbts.2016.09.008 · Cited by 237
Molecular mechanisms in liver repair and regeneration: from physiology to therapeutics
Ma, X., Huang, T., Chen, X., Li, Q., Liao, M., Fu, L., Huang, J., Yuan, K., Wang, Z., & Zeng, Y. (2025) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-024-02104-8 · Cited by 133
Alveolar rhabdomyosarcoma–associated PAX3-FOXO1 promotes tumorigenesis via Hippo pathway suppression
Crose, L. E. S., Galindo, K. A., Kephart, J. G., Chen, C., Fitamant, J., Bardeesy, N., Bentley, R. C., Galindo, R. L., Ashley Chi, J.-T., & Linardic, C. M. (2014) · Journal of Clinical Investigation · doi:10.1172/jci67087 · Cited by 124
“Importantly, recent studies show that MOB1 deficiency in mice leads to spontaneous tumor susceptibility in many tissue types, including the induction of osteosarcomas and fibro-sarcomas (65).”
Prevalence of the Hippo Effectors YAP1/TAZ in Tumors of Soft Tissue and Bone
Isfort, I., Elges, S., Cyra, M., Berthold, R., Renner, M., Mechtersheimer, G., Åman, P., Larsson, O., Ratner, N., Hafner, S., et al. (2019) · Scientific Reports · doi:10.1038/s41598-019-56247-8 · Cited by 35
Expression patterns of Yes-associated protein 1 in the developing mouse liver
Wei, W., Lotto, J., & Hoodless, P. A. (2018) · Gene Expression Patterns · doi:10.1016/j.gep.2018.04.003 · Cited by 3
Metadata
- Authors
- Nishio, M., Hamada, K., Kawahara, K., Sasaki, M., Noguchi, F., Chiba, S., Mizuno, K., Suzuki, S. O., Dong, Y., Tokuda, M., Morikawa, T., Hikasa, H., Eggenschwiler, J., Yabuta, N., Nojima, H., Nakagawa, K., Hata, Y., Nishina, H., Mimori, K., Mori, M., Sasaki, T., Mak, T. W., Nakano, T., Itami, S., & Suzuki, A.
- Venue
- Journal of Clinical Investigation
- Published
- 2012-11-12
- Volume
- 122
- Issue
- 12
- Pages
- 4505-4518
- ISSN
- 0021-9738 (ISSN-L)
- OpenAlex
- W2171141151
- Cited by
- 149
- References
- 6
- FWCI
- 4.83
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.